alanine has been researched along with Cognition Disorders in 19 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Since oral administration of d-alanine, an agonist that binds to the glycine site of N-methyl-d-aspartate (NMDA) receptors, improves the positive and cognitive symptoms of patients with schizophrenia, measurement of endogenous plasma alanine levels could serve as a clinical marker for schizophrenia severity and improvement." | 9.14 | Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP). ( Arai, H; Hanzawa, R; Hatano, T; Maeshima, H; Ohnuma, T; Sakai, Y; Shibata, N; Suzuki, T, 2010) |
| "Since oral administration of d-alanine, an agonist that binds to the glycine site of N-methyl-d-aspartate (NMDA) receptors, improves the positive and cognitive symptoms of patients with schizophrenia, measurement of endogenous plasma alanine levels could serve as a clinical marker for schizophrenia severity and improvement." | 5.14 | Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP). ( Arai, H; Hanzawa, R; Hatano, T; Maeshima, H; Ohnuma, T; Sakai, Y; Shibata, N; Suzuki, T, 2010) |
| "Safinamide (Xadago(®)) is an oral α-aminoamide derivative developed by Newron for the treatment of Parkinson's disease (PD)." | 2.52 | Safinamide: first global approval. ( Deeks, ED, 2015) |
| "Alzheimer's disease is thought to be caused by increased formations of neurotoxic amyloid beta (A beta) peptides, which give rise to the hallmark amyloid plaques." | 2.45 | Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease. ( Dean, RA; Henley, DB; May, PC; Siemers, ER, 2009) |
| "An unresolved debate in Alzheimer's disease (AD) is whether amyloid plaques are pathogenic, causing overt physical disruption of neural circuits, or protective, sequestering soluble forms of amyloid-β (Aβ) that initiate synaptic damage and cognitive decline." | 1.40 | Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. ( Chiang, AC; Cirrito, JR; Fowler, SW; Jankowsky, JL; Larson, ME; Lesné, SE; Savjani, RR; Schuler, DR; Sherman, MA, 2014) |
| "In these families, FTLD cosegregates with ALS." | 1.36 | Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations. ( Borghero, G; Brunetti, M; Calvo, A; Chiò, A; Cistaro, A; Marrosu, MG; Moglia, C; Montuschi, A; Murru, MR; Mutani, R; Ossola, I; Restagno, G; Schymick, JC; Ticca, A; Traynor, BJ, 2010) |
| "The Timothy syndrome is a multisystem disorder associated with the mutation of a Gly residue (G402 or G406) in the Ca(v)1." | 1.35 | Introduction into Ca(v)2.1 of the homologous mutation of Ca(v)1.2 causing the Timothy syndrome questions the role of V421 in the phenotypic definition of P-type Ca(2+) channel. ( Cens, T; Charnet, P; Leyris, JP, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.26) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ochoa, JF | 1 |
| Alonso, JF | 1 |
| Duque, JE | 1 |
| Tobón, CA | 1 |
| Baena, A | 1 |
| Lopera, F | 2 |
| Mañanas, MA | 1 |
| Hernández, AM | 1 |
| Koros, C | 1 |
| Simitsi, A | 1 |
| Prentakis, A | 1 |
| Beratis, I | 1 |
| Papadimitriou, D | 1 |
| Kontaxopoulou, D | 1 |
| Fragkiadaki, S | 1 |
| Papagiannakis, N | 1 |
| Seibyl, J | 1 |
| Marek, K | 1 |
| Papageorgiou, SG | 1 |
| Trapali, XG | 1 |
| Stamelou, M | 1 |
| Stefanis, L | 1 |
| Venkateswaran, S | 1 |
| McMillan, HJ | 1 |
| Doja, A | 1 |
| Humphreys, P | 1 |
| Fowler, SW | 1 |
| Chiang, AC | 1 |
| Savjani, RR | 1 |
| Larson, ME | 1 |
| Sherman, MA | 1 |
| Schuler, DR | 1 |
| Cirrito, JR | 1 |
| Lesné, SE | 1 |
| Jankowsky, JL | 1 |
| Deeks, ED | 1 |
| Liu-Seifert, H | 1 |
| Siemers, E | 1 |
| Price, K | 1 |
| Han, B | 1 |
| Selzler, KJ | 1 |
| Henley, D | 1 |
| Sundell, K | 1 |
| Aisen, P | 1 |
| Cummings, J | 2 |
| Raskin, J | 1 |
| Mohs, R | 1 |
| Sydow, A | 1 |
| Hochgräfe, K | 1 |
| Könen, S | 1 |
| Cadinu, D | 1 |
| Matenia, D | 1 |
| Petrova, O | 1 |
| Joseph, M | 1 |
| Dennissen, FJ | 1 |
| Mandelkow, EM | 1 |
| Cens, T | 1 |
| Leyris, JP | 1 |
| Charnet, P | 1 |
| Rönnbäck, A | 1 |
| Zhu, S | 1 |
| Dillner, K | 1 |
| Aoki, M | 1 |
| Lilius, L | 1 |
| Näslund, J | 1 |
| Winblad, B | 1 |
| Graff, C | 1 |
| Henley, DB | 1 |
| May, PC | 1 |
| Dean, RA | 1 |
| Siemers, ER | 1 |
| Hatano, T | 1 |
| Ohnuma, T | 2 |
| Sakai, Y | 2 |
| Shibata, N | 2 |
| Maeshima, H | 2 |
| Hanzawa, R | 2 |
| Suzuki, T | 1 |
| Arai, H | 2 |
| Chiò, A | 1 |
| Calvo, A | 1 |
| Moglia, C | 1 |
| Restagno, G | 1 |
| Ossola, I | 1 |
| Brunetti, M | 1 |
| Montuschi, A | 1 |
| Cistaro, A | 1 |
| Ticca, A | 1 |
| Traynor, BJ | 1 |
| Schymick, JC | 1 |
| Mutani, R | 1 |
| Marrosu, MG | 1 |
| Murru, MR | 1 |
| Borghero, G | 1 |
| Peng, Y | 1 |
| Luo, XJ | 1 |
| Chen, XP | 1 |
| Li, LX | 1 |
| Wan, LY | 1 |
| He, S | 1 |
| Chen, XN | 1 |
| Wu, K | 1 |
| MacPherson, SE | 1 |
| Parra, MA | 1 |
| Moreno, S | 1 |
| Della Sala, S | 1 |
| Higa, M | 1 |
| Kitazawa, M | 1 |
| Hotta, Y | 1 |
| Katsuta, N | 1 |
| Takebayashi, Y | 1 |
| Evans, ML | 1 |
| Hopkins, D | 1 |
| Macdonald, IA | 1 |
| Amiel, SA | 1 |
| Yaffe, K | 1 |
| Kanaya, AM | 1 |
| Lindquist, K | 1 |
| Hsueh, WC | 1 |
| Cummings, SR | 1 |
| Beamer, B | 1 |
| Newman, A | 1 |
| Rosano, C | 1 |
| Li, R | 1 |
| Harris, T | 1 |
| Burns, R | 1 |
| Thomas, DW | 1 |
| Barron, VJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of γ-Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 Versus Placebo[NCT00594568] | Phase 3 | 1,537 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Effect of LY450139 a y-Secretase Inhibitor, on the Progression of Alzheimer's Disease as Compared With Placebo[NCT00762411] | Phase 3 | 1,111 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer's Disease as Compared With Placebo[NCT00905372] | Phase 3 | 1,000 participants (Anticipated) | Interventional | 2009-05-31 | Completed | ||
| Effect of Passive Immunization on the Progression of Alzheimer's Disease: LY2062430 Versus Placebo[NCT00904683] | Phase 3 | 1,040 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
ADAS-Cog11 consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.59 |
| 100 mg LY450139 | 7.57 |
| 140 mg LY450139 | 7.90 |
ADAS-Cog11 was used as a primary efficacy measure. It consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.19 |
| 100 mg LY450139 | 7.29 |
| 140 mg LY450139 | 7.68 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.97 |
| 100 mg LY450139 | 8.27 |
| 140 mg LY450139 | 8.41 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 6.52 |
| 100 mg LY450139 | 7.98 |
| 140 mg LY450139 | 8.33 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.90 |
| 100 mg LY450139 | 9.30 |
| 140 mg LY450139 | 9.89 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 7.42 |
| 100 mg LY450139 | 8.97 |
| 140 mg LY450139 | 9.48 |
ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -9.26 |
| 100 mg LY450139 | -9.15 |
| 140 mg LY450139 | -11.73 |
ADCS-ADL is a 23-item inventory developed as a Rater-administered questionnaire answered by the participant's caregiver. It measures performance of basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -8.76 |
| 100 mg LY450139 | -10.13 |
| 140 mg LY450139 | -12.70 |
Concentration of an amino peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | -86.16 |
| 100 mg LY450139 | 23.27 |
| 140 mg LY450139 | -40.51 |
A radioactive tracer for PET that is a ligand for amyloid called AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | 0.08 |
| 100 mg LY450139 | 0.06 |
| 140 mg LY450139 | 0.09 |
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 2.31 |
| 100 mg LY450139 | 2.73 |
| 140 mg LY450139 | 3.04 |
EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver's impression of participant's overall health state; scores range from 0 to 100; Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -1.41 |
| 100 mg LY450139 | -7.49 |
| 140 mg LY450139 | -5.33 |
MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, and ability to name objects, follow verbal and written commands, write a sentence, and copy figures) in elderly participants. The total score ranges from 0 to 30; Lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | -2.95 |
| 100 mg LY450139 | -3.14 |
| 140 mg LY450139 | -3.71 |
NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Placebo | 1.92 |
| 100 mg LY450139 | 3.31 |
| 140 mg LY450139 | 4.15 |
Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | 9.75 |
| 100 mg LY450139 | -6.26 |
| 140 mg LY450139 | -5.13 |
Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| Placebo | -0.08 |
| 100 mg LY450139 | -0.12 |
| 140 mg LY450139 | -0.11 |
Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (caregiving time, work status) and participants (accommodation and healthcare resource utilization) was collected from baseline and follow-up interviews; Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | hospitalizations/participant (Least Squares Mean) |
|---|---|
| Placebo | 0.55 |
| 100 mg LY450139 | 0.66 |
| 140 mg LY450139 | 0.83 |
Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | 75.11 |
| 100 mg LY450139 | 20.50 |
| 140 mg LY450139 | 61.00 |
Model estimated apparent oral clearance. Clearance is defined as the volume of plasma that is completely cleared of drug (LY450139) per unit time. (NCT00594568)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liter per hour (L/h) (Geometric Mean) |
|---|---|
| LY450139 | 18.8 |
Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which the drug distributes in the body. (NCT00594568)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liter (L) (Geometric Mean) |
|---|---|
| LY450139 | 66.8 |
Concentration of amino acid peptide, known as Aβ 1-42, in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), 52 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| Placebo | 3.86 |
| 100 mg LY450139 | -5.97 |
| 140 mg LY450139 | -19.95 |
The vMRI assessment of left and right hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00594568)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | cubic millimeter (mm^3) (Least Squares Mean) | |
|---|---|---|
| Left Hippocampal Volume | Right Hippocampal Volume | |
| 100 mg LY450139 | -75.34 | -93.89 |
| 140 mg LY450139 | -107.62 | -112.40 |
| Placebo | -96.54 | -108.69 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 6.00 |
| Placebo | 5.89 |
ADAS-Cog14 is ADAS-Cog11 augmented with delayed free recall, digit cancellation, and maze completion measures. A score of 0 to 10 for delayed free recall and a conversion code of 0 to 5 for digit cancellation and maze completion provide total score ranges for this extended ADAS-Cog14 of 0 to 90. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 9.23 |
| Placebo | 8.32 |
The cognitive subscale of ADAS (ADAS Cog11) consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 4.81 |
| Placebo | 4.85 |
The cognitive subscale of the ADAS (ADAS Cog11) was used as a primary efficacy measure and consists of 11 items assessing areas of function most typically impaired in Alzheimer's disease (AD): orientation, verbal memory, language, and praxis. The scale ranges from 0 to 70, with higher scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 7.37 |
| Placebo | 6.77 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 5.33 |
| Placebo | 5.14 |
ADAS-Cog12 is ADAS-Cog11 augmented with delayed free recall measure, resulting in a total score ranging from 0 to 80. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 10.09 |
| Placebo | 10.34 |
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 16 weeks following treatment cessation
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -8.88 |
| Placebo | -7.68 |
The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The total score ranges from 0 to 78, with lower scores indicating greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -10.49 |
| Placebo | -9.77 |
Concentration of an amino acid peptide known as Aβ 1-42 in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 19.20 |
| Placebo | -21.39 |
A radioactive tracer for PET that is a ligand for amyloid called [18F]-AV-45. This permits the visualization of amyloid in the brains of Alzheimer's participants. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the cerebellar gray matter. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -0.36 |
| Placebo | 0.16 |
CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 3.05 |
| Placebo | 4.00 |
MMSE is a brief screening instrument used to assess cognitive function (orientation, memory, attention, ability to name objects, follow verbal/written commands, write a sentence, and copy figures) in elderly participants. Total score ranges from 0 to 30; lower score indicates greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -3.56 |
| Placebo | -3.35 |
NPI assesses psychopathology in participants with dementia and other neurologic disorders. Information is obtained from a caregiver familiar with the participant's behavior. Total score ranges from 12 to 144; higher scores indicate greater disease severity. Least Squares (LS) Mean value was controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 2.94 |
| Placebo | 3.84 |
Concentration of p-tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 7.94 |
| Placebo | 14.75 |
Measurement of local cerebral glucose metabolism by PET using the radioactive tracer 18F-FDG. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the Pons. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | ratio (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -0.13 |
| Placebo | -0.08 |
Assess QoL for AD: participant rates mood, relationships, memory, finances, physical condition, and overall QoL assessment. Each of 13 items, rated on a 4-point scale. Sum of items=total score (range: 13 to 52). Higher scores indicate greater QoL. Participant's primary caregiver asked to complete same measure. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -1.83 |
| Placebo | -1.05 |
Concentration of total tau in spinal fluid. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -11.60 |
| Placebo | 117.88 |
EQ-5D (proxy version) measures mobility, self-care, usual activities, pain/discomfort, anxiety/depression; each has 3 severity levels (no, some, severe problems) coded to a 1-digit number (1-3). Digits are combined into 5-digit number describing health state. Numerals 1-3 are not added for total score. VAS assesses caregiver's impression of participant's overall health state; scores range: 0 to 100. Lower scores indicate greater disease severity. Least Squares (LS) Mean value controlled for baseline value, age, investigator, visit, and concomitant standard of care (SOC) medication. (NCT00762411)
Timeframe: Baseline (randomization), 76 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -4.46 |
| Placebo | -3.38 |
Assesses healthcare resource utilization (formal and informal care). Information gathered on both caregivers (care-giving time, work status) and participants (accommodation and healthcare resource utilization) was gathered from baseline and follow-up interviews. Reported number of hospitalizations per participant up to 76 weeks. Least Squares (LS) Mean value was controlled for age and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | number of hospitalizations (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | 0.72 |
| Placebo | 0.82 |
Model estimated apparent oral clearance. Clearance is defined as the volume of plasma which is completely cleared of drug (LY450139) per unit time. (NCT00762411)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liters per hour (L/h) (Geometric Mean) |
|---|---|
| 140 mg LY450139 | 18.9 |
Model-estimated apparent volume of distribution. Volume of distribution is a measure of the extent to which drug distributes in the body. (NCT00762411)
Timeframe: 6 weeks, 12 weeks, and 52 weeks
| Intervention | liters (L) (Geometric Mean) |
|---|---|
| 140 mg LY450139 | 66.1 |
Concentration of amino acid peptide known as Aβ 1-42 in plasma. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), 52 weeks
| Intervention | picogram per milliliter (pg/mL) (Least Squares Mean) |
|---|---|
| 140 mg LY450139 | -16.03 |
| Placebo | 76.37 |
The vMRI assessment of right and left hippocampal volume is reported. Least Squares (LS) Mean value was controlled for baseline value, age, and investigator. (NCT00762411)
Timeframe: Baseline (randomization), up to 76 weeks
| Intervention | cubic millimeter (mm^3) (Least Squares Mean) | |
|---|---|---|
| Right Hippocampal Volume | Left Hippocampal Volume | |
| 140 mg LY450139 | -158.50 | -84.41 |
| Placebo | -73.60 | -111.27 |
2 reviews available for alanine and Cognition Disorders
| Article | Year |
|---|---|
Safinamide: first global approval.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Cognition Disorders; Drug Approval; Dyskinesia | 2015 |
Development of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease.
Topics: Alanine; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Azepines; Cholinesterase | 2009 |
2 trials available for alanine and Cognition Disorders
| Article | Year |
|---|---|
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Antibodies, Monoclonal, Humanized; Antipsychoti | 2015 |
Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP).
Topics: Adolescent; Adult; Alanine; Case-Control Studies; Chromatography, High Pressure Liquid; Cluster Anal | 2010 |
15 other studies available for alanine and Cognition Disorders
| Article | Year |
|---|---|
Precuneus Failures in Subjects of the PSEN1 E280A Family at Risk of Developing Alzheimer's Disease Detected Using Quantitative Electroencephalography.
Topics: Adult; Alanine; Alzheimer Disease; Brain Mapping; Brain Waves; Cognition Disorders; Electroencephalo | 2017 |
123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
Topics: Adult; Alanine; alpha-Synuclein; Cognition Disorders; Cohort Studies; Corpus Striatum; Dopamine; Fem | 2018 |
Adolescent onset cognitive regression and neuropsychiatric symptoms associated with the A140V MECP2 mutation.
Topics: Activities of Daily Living; Adolescent; Adolescent Development; Age of Onset; Alanine; Cognition; Co | 2014 |
Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; An | 2014 |
Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD.
Topics: Age Factors; Aging; Alanine; Alzheimer Disease; Animals; Astrocytes; Cognition Disorders; Cytokines; | 2016 |
Introduction into Ca(v)2.1 of the homologous mutation of Ca(v)1.2 causing the Timothy syndrome questions the role of V421 in the phenotypic definition of P-type Ca(2+) channel.
Topics: Alanine; Animals; Arginine; Arrhythmias, Cardiac; Calcium; Calcium Channels, L-Type; Calcium Channel | 2008 |
Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model.
Topics: Age Factors; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2011 |
Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations.
Topics: Adult; Aged; Alanine; Amyotrophic Lateral Sclerosis; Brain; Cognition Disorders; DNA-Binding Protein | 2010 |
What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease?
Topics: Alanine; Alzheimer Disease; Amyloid; Amyloid Precursor Protein Secretases; Azepines; Cognition Disor | 2010 |
[Association of PPARgamma2 Pro12Ala polymorphism and cognitive dysfunction in hypertension patients].
Topics: Aged; Alanine; Alleles; Cognition Disorders; Female; Gene Frequency; Humans; Hypertension; Male; Mid | 2010 |
Dual task abilities as a possible preclinical marker of Alzheimer's disease in carriers of the E280A presenilin-1 mutation.
Topics: Adult; Alanine; Alzheimer Disease; Analysis of Variance; Biomarkers; Cognition Disorders; Female; Gl | 2012 |
No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Alanine; Antipsychotic Agents; Basal Ganglia Diseases; Biomarkers; Brief Ps | 2012 |
Alanine infusion during hypoglycaemia partly supports cognitive performance in healthy human subjects.
Topics: Adult; Alanine; Blood Glucose; Cognition Disorders; Glucose Clamp Technique; Hormones; Humans; Hypog | 2004 |
PPAR-gamma Pro12Ala genotype and risk of cognitive decline in elders.
Topics: Aged; Aging; Alanine; Black People; Cognition Disorders; Female; Genotype; Humans; Longitudinal Stud | 2008 |
Reversible encephalopathy possibly associated with bismuth subgallate ingestion.
Topics: Adult; Aged; Alanine; Arginine; Bismuth; Brain Diseases; Cerebellum; Chromatography; Cognition Disor | 1974 |